Analyst Group Comment on that STENOCARE’s Astrum Oil has been Approved for Sales in Norway

STENOCARE announced on December 2nd that the company’s premium product, the Astrum oil, has been approved for sales on the Norwegian market. The product is expected to have several benefits compared to the medical cannabis oil available today, including a higher, more uniform, and faster uptake in the blood. The product, Astrum 10-10 oil Stenocare, with 10 mg/ml THC and 10 mg/ml CBD, is expected to be available for patients in Norway within the next 30 days.

Länk till analysen i sin helhet: https://analystgroup.se/kommentarer/comment-on-that-stenocares-astrum-oil-has-been-approved-for-sales-in-norway/